Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.

Many patients who achieved clear skin with tapinarof treatment maintained low disease activity after a treatment-free interval.

F RIDAY, March 14, 2025 (HealthDay News) -- Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease activity after about 80 days ...

FRIDAY, March 14, 2025 (HealthDay News) -- Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease activity after about 80 days off ...

David Rosmarin, M.D., of the Indiana University School of Medicine in Indianapolis, and colleagues conducted a 48-week open-label, long-term extension study (ADORING 3) evaluating tapinarof in 728 ...

Organon has recently announced new results from the phase 3 ADORING 3 open-label, long-term extension study evaluating tapinarof cream, 1% (VTAMA), for the treatment of atopic dermatitis (AD). The ...

From new topical dermatology treatments for atopic dermatitis to the first nasal spray to treat type 1 allergic reactions, these are our top FDA approvals of 2024. Arcutis seeks FDA approval for ...